AVBP / ArriVent BioPharma, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

‌Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2025 Financial Results ● Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 ● Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors ● Top-line firmonertin

Loan and Security Agreement, dated May 8, 2025, by and between Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, and the Registrant.

‌Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, amended and restated, modified or supplemented, this “Agreement”) is dated as of the Effective Date by and between (a) SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (“Bank”), and (b) ARRIVENT BIOPHARMA, INC., a Delaware corporation (“Borrower”). The parties agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARRI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 ARRIVENT BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commissio

Amended and Restated Non-Employee Director Compensation Policy.

‌Exhibit 10.1 ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (March 20, 2025) The Board of Directors of ArriVent BioPharma, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective as of March 2

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designa

Exhibit 99.1 ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, PA, July 21, 2025 (GLOBE NEWSWIRE) - ArriVent BioPharma, Inc. (Company or ArriVent) (Nasd

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Form of Pre-Funded Warrant.

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 ARRIVENT BIOPHARMA, INC. ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Exhibit 99.1 ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants NEWTOWN SQUARE, PA, July 1, 2025 – ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shar

2,482,692 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,363,469 Shares of Common Stock

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(5)  Registration No. 333-284661 Prospectus Supplement (To Prospectus dated February 3, 2025) 2,482,692 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 1,363,469 Shares of Common Stock We are offering 2,482,692 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase up

Calculation of Filing Fee Tables (Form Type) ArriVent BioPharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) ArriVent BioPharma, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 ARRIVENT BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission F

Underwriting Agreement, dated July 1, 2025, by and between the Company and Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Guggenheim Securities, LLC.

   Exhibit 1.1   ArriVent BioPharma, Inc.   2,482,692 Shares of Common Stock   Pre-Funded Warrants to Purchase up to 1,363,469 Shares of Common Stock   Underwriting Agreement   July 1, 2025   Goldman Sachs & Co. LLC Citigroup Global Markets Inc. Guggenheim Securities, LLC        As representatives (the “Representatives”) of the several Underwriters          named in Schedule I hereto,   c/o Goldma

Subject to Completion, Dated July 1, 2025

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 ARRIVENT BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study 16.0 months median progression free survival (mPFS) with fir

Exhibit 99.1 Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study 16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 ARRIVENT BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Amended and Restated Non-Employee Director Compensation Policy.

‌Exhibit 10.3 ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (March 20, 2025) The Board of Directors of ArriVent BioPharma, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective as of March 2

ArriVent BioPharma Reports First Quarter 2025 Financial Results

‌Exhibit 99.1 ArriVent BioPharma Reports First Quarter 2025 Financial Results ● Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations ● Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 ● First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARR

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission F

Exclusive License Agreement, dated January 21, 2025, by and between Lepu Biopharma Co., Ltd and the Registrant.

Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of January 21, 2025 (the “Effective Date”) by and between LEPU BIOPHARMA CO., LTD., a corporation organized and existing under the laws of the People’s Republic of China and having a place of business at No. 651 Lianheng Road, Minhang District, Shanghai, China (“Lepu”), and ARRIVENT BIOP

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Exhibit 99.1 ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors NEWTOWN SQUARE, PA, April 28, 2025 (GLOBE NEWSWIRE) - ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Letter from KPMG LLP, dated March 13, 2025.

‌Exhibit 16.1 March 13, 2025 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for ArriVent BioPharma, Inc. (the Company) and, under the date of March 3, 2025, we reported on the financial statements of the Company as of and for the years ended December 31, 2024 and 2023. On March 11, 2025, we were dismissed. We have read the C

ArriVent BioPharma Reports Full Year 2024 Financial Results

‌Exhibit 99.1 ArriVent BioPharma Reports Full Year 2024 Financial Results ● First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations ● Global pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollment ● Selected next-generation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARRIVENT

Insider Trading Policy.

‌Exhibit 19 Page 1 of 17 Arrivent biopharma, Inc. INSIDER TRADING POLICY TABLE OF CONTENTS Page I.The Need for an Insider Trading Policy‌2 II.What is Material Non-Public Information?‌3 III.The Consequences of Insider Trading‌4 IV.Our Policy‌5 V.Individual Responsibility‌10 VI.Additional Prohibited Transactions‌11 VII.Post-Termination Transactions‌12 VIII.Company Assistance‌12 IX.Certifications‌12

As filed with the Securities and Exchange Commission on March 3, 2025

As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ARRIVENT BIOPHARMA, INC.

As filed with the Securities and Exchange Commission on February 3, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 3, 2025 Registration No.

Form of Senior Indenture.

Exhibit 4.6 ArriVent BioPharma, Inc. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5

, dated as of February 3, 2025, by and between ArriVent BioPharma, Inc. andJefferies

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 3, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s commo

Form of Subordinated Indenture.

Exhibit 4.7 ArriVent BioPharma, Inc. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 31

Calculation of Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) ArriVent BioPharma, Inc.

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Exhibit 99.1 ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers · Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers · First Investigational New Drug (IND) submission planned for 1H 2025 · Expands ArriVen

Regulation FD Disclosure, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commissi

AVBP / ArriVent BioPharma, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment

SC 13G 1 d1153804913g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* ArriVent BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value per Share (Title of Class of Securities) 04272N102 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri

AVBP / ArriVent BioPharma, Inc. / HILLHOUSE CAPITAL ADVISORS, LTD. - ARRIVENT BIOPHARMA, INC. Passive Investment

SC 13G 1 p24-3174sc13g.htm ARRIVENT BIOPHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ArriVent BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 04272N102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Ch

Amended and Restated Research and Collaboration Agreement, dated August 9, 2024, by and between Aarvik Therapeutics, Inc. and the Registrant.

Exhibit 10.1 AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT This AMENDED AND RESTATED RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of August 9, 2024 (the “Restated Agreement Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent BioPha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929

ArriVent BioPharma Reports Third Quarter 2024 Financial Results Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for fir

‌Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2024 Financial Results Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as o

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commiss

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-1 2 p24-3174exhibit1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addition

AVBP / ArriVent BioPharma, Inc. / Sofinnova Venture Partners XI, L.P. - SC 13G Passive Investment

SC 13G 1 tm2427940d2sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* ArriVent Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value per Share (Title of Class of Securities) 04272N102 (CUSIP Num

AVBP / ArriVent BioPharma, Inc. / Octagon Capital Advisors LP Passive Investment

SC 13G 1 avbp1011241sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ArriVent BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 04272N102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriat

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commiss

Arrivent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer 81.8% ORR by BICR and 63.6% confirmed ORR by

Exhibit 99.1 Arrivent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARRI

Research and Collaboration Agreement Between Jiangsu Alphamab Biopharmaceuticals Co., Ltd and Arrivent Biopharma, Inc.

Exhibit 10.1 RESEARCH AND COLLABORATION AGREEMENT BETWEEN JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD AND ARRIVENT BIOPHARMA, INC. June 2, 2024 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. This RESEARCH AND COLLABORATI

ArriVent BioPharma Reports Second Quarter 2024 Financial Results Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium pr

Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2024 Financial Results Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) ArriVent to host virtual webinar on these interim analyses of Phase 1b data

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorpor

ArriVent Appoints Kristine Peterson to its Board of Directors

Exhibit 99.1 ArriVent Appoints Kristine Peterson to its Board of Directors NEWTON SQUARE, PA – April 22, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leaders

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and mil

Exhibit 99.1 ArriVent Announces a Multi-Target ADC Collaboration with Alphamab Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, CHINA and NEWTOWN SQUARE, PA – June 5, 2024 – ArriVent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 ARRIVENT BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission F

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

Exhibit 99.1 ArriVent Appoints John Hohneker, M.D., to its Board of Directors NEWTON SQUARE, PA – May 16, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharm

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission Fi

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Exhibit 99.1 ArriVent BioPharma Reports First Quarter 2024 Financial Results ● Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual Meeting ● Dosed first patient in Phase 1b combination study of firmonertinib and ICP-189 for advanced or metastatic non-small cell lung cancer (“NSCLC”) with epidermal growth factor rece

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARR

ArriVent Appoints Kristine Peterson to its Board of Directors

Exhibit 99.1 ArriVent Appoints Kristine Peterson to its Board of Directors NEWTON SQUARE, PA – April 22, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leaders

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

Description of Securities.

Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ArriVent Biopharma, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share. Unless the context otherwise requires, all references to “we”,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41929 ARRIVENT

ArriVent Biopharma Reports Full Year 2023 Financial Results

Exhibit 99.1 ArriVent Biopharma Reports Full Year 2023 Financial Results · Company progresses the development of furmonertinib with a data readout planned for 2024 · Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration · Completed $201 million initial public offering (“IPO”) in January 2024 NEWTOWN SQUARE, PA, March 28, 2024 (GLOBE NEWSWIRE) - ArriVent Bi

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commission

AVBP / ArriVent BioPharma, Inc. / LAV Fund VI, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 ea193269-13glav6arrivent.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ArriVent BioPharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 04272N 102 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this Sta

Exhibit 99.1: Agreement of Joint Filing

EX-99.1 2 ea193269ex99-1arrivent.htm AGREEMENT OF JOINT FILING Exhibit 99.1 AGREEMENT OF JOINT FILING The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of ArriVent BioPharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Dated: February 13, 2024 LAV FU

Form of Lock-Up Agreement.

ArriVent Biopharma, Inc. Lock-Up Agreement August 25, 2023 Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As Representatives of the several Underwriters named in Schedule I to the Underwriting Agreement c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Citigroup Global Markets Inc. 388 Greenwich Stre

Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia Partners IV, L.P., and OrbiMed Advisors IV Limited.

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated January 30, 2024, with respect to the common stock of ArriVent BioPharma, Inc.

AVBP / ArriVent BioPharma, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ArriVent BioPharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04272N102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. OrbiMed Advisors IV Limited 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephon

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ARRIVENT BIOPHARMA, INC.

As filed with the Securities and Exchange Commission on February 2, 2024

As filed with the Securities and Exchange Commission on February 2, 2024 Registration No.

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-41929) filed with the SEC on January 30, 2024).

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ArriVent BioPharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (File No. 001-41929) filed with the SEC on January 30, 2024).

Exhibit 3.2 ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS (Effective as of January 30, 2024) ARTICLE I - STOCKHOLDERS Section 1.       Annual Meeting. An annual meeting of the stockholders of ArriVent BioPharma, Inc. (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, s

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 ARRIVENT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41929 86-3336099 (State or other jurisdiction of incorporation) (Commissi

9,722,222 Shares ArriVent BioPharma, Inc. Common Stock

TABLE OF CONTENTS  Filed Purusuant to Rule 424(b)(4)  Registration Nos. 333-276397 and 333-276699   PROSPECTUS 9,722,222 Shares ArriVent BioPharma, Inc. Common Stock This is an initial public offering of shares of common stock of ArriVent BioPharma, Inc. We are offering 9,722,222 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial p

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ArriVent BioPharma, Inc.

As filed with the Securities and Exchange Commission on January 25, 2024.

As filed with the Securities and Exchange Commission on January 25, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARRIVENT BIOPHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary S

ArriVent BioPharma, Inc. 18 Campus Boulevard, Suite 100 Newtown Square, PA 19073

ArriVent BioPharma, Inc. 18 Campus Boulevard, Suite 100 Newtown Square, PA 19073 January 23, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Christopher Edwards and Suzanne Hayes Re: ArriVent BioPharma, Inc. Registration Statement on Form S-1, as amended (File No. 333-276397) Request for

Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, as amended, as currently in effect

Exhibit 3.1.1 Certificate Of Amendment To Second Amended and Restated Certificate of Incorporation Of ArriVent BioPharma, Inc. ArriVent BioPharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify, ONE:           That, the name of the Corpo

As filed with the Securities and Exchange Commission on January 23, 2024.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 23, 2024.

registration statement on Form 8-A12B, that we filed with the SEC on January 23, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ARRIVENT BIOPHARMA, INC.

[Signature Page Follows]

Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 Jefferies LLC 520 Madison Avenue New York, New York 10022 Citigroup Global Markets Inc. 383 Greenwich Street New York, New York 10013 January 23, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christopher Edwards Suzanne Hayes Division of Cor

2024 Employee, Director and Consultant Equity Incentive Plan, form of stock option agreement and form of restricted stock agreement thereunder

Exhibit 10.3 ARRIVENT BIOPHARMA, INC. 2024 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1.             DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this ArriVent Biopharma, Inc. 2024 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unles

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 ArriVent BioPharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2)(3) Fee Rate Amount of Registration Fee(4) Fees to Be Paid Equity Common Stock, par value $0.0001 per share 457(a)

* * * * * Boston Los Angeles New York San Diego San Francisco TORONTO Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com January 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christopher Edwards and Suzanne Hayes, Office of Life Sciences Re: ArriVent BioPharma, Inc. Registration Statement on Form S-1 Filed January 5, 2024 File No. 333-276397 (the “Registration Stat

As filed with the Securities and Exchange Commission on January 22, 2024.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 22, 2024.

Form of Underwriting Agreement

Exhibit 1.1 ArriVent BioPharma, Inc. Common Stock Underwriting Agreement [ · ], 2024 Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Citigro

ArriVent BioPharma, Inc. Executive Severance Plan

Exhibit 10.4 ARRIVENT BIOPHARMA, Inc. EXECUTIVE SEVERANCE PLAN 1.            Establishment; Purpose. ArriVent, Inc. (the “Company”) hereby establishes as of [●], 2023 an unfunded severance benefit plan (this “Plan”) for its Eligible Employees in order to establish the conditions under which the Eligible Employees will receive the severance payments and benefits described herein if their employment

Boston Los Angeles New York San Diego San Francisco toronto Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. FOIA CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. § 200.83 BY ARRIVENT BIOPHARMA, INC. IN CONNECTION WITH REGISTRATIO

One Financial Center Boston, MA 02111 617 542 6000 mintz.com CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE OMITTED PORTIONS, WHICH HAVE BEEN REPLACED WITH THE PLACEHOLDER “[***].” January 11, 2024 VIA EDGAR AND COURIER Securities and Exchange Commission Division of Corporation Finance

Joint Clinical Collaboration Agreement, by and between the Registrant and Shanghai Allist Pharmaceuticals Co., Ltd., dated December 24, 2021

Exhibit 10.13 JOINT CLINICAL COLLABORATION AGREEMENT This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New D

ArriVent BioPharma, Inc. Executive Severance Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-276397) filed on January 5, 2024).

Exhibit 10.4 ARRIVENT BIOPHARMA, Inc. EXECUTIVE SEVERANCE PLAN 1.            Establishment; Purpose. ArriVent, Inc. (the “Company”) hereby establishes as of [●], 2023 an unfunded severance benefit plan (this “Plan”) for its Eligible Employees in order to establish the conditions under which the Eligible Employees will receive the severance payments and benefits described herein if their employment

Offer Letter Agreement, by and between the Registrant and Stuart Lutzker, M.D., Ph.D., dated May 1, 2021

Exhibit 10.8 May 1, 2021 Stuart Lutzker Dear Stuart, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are m

Non-Employee Director Compensation Policy

Exhibit 10.5 ARRIVENT BIOPHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (, 2023) The Board of Directors of ArriVent BioPharma, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective upon the completion of the Company’s initial public offering (“E

ArriVent BioPharma, Inc. Clawback Policy

Exhibit 10.6 ARRIVENT BIOPHARMA, INC. CLAWBACK POLICY I.             Introduction The Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Th

Second Amended and Restated Bylaws of the Registrant, as currently in effect

Exhibit 3.3 ARRIVENT BIOPHARMA, INC. SECOND AMENDED AND RESTATED BYLAWS Adopted as of December 16, 2022 1 Table of Contents Page(s) ARTICLE I STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Notice of Meetings 1 Section 4. Quorum 2 Section 5. Organization 2 Section 6. Conduct of Business 2 Section 7. Proxies and Voting 2 Section 8. Action without Meeting 3 Sectio

Form of Indemnification Agreement

Exhibit 10.1 Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made and entered into this []th day of [], 202[ ], by and between ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). Recitals Whereas, qualified persons are reluctant to serve corporations as directors or otherwise unless they are provided with broad indemnification and

Offer Letter Agreement, by and between the Registrant and Zhengbin (Bing) Yao, Ph.D., dated May 5, 2021

Exhibit 10.7 May 5, 2021 Bing Yao Dear Bing I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are met and yo

License Agreement, by and between the Registrant and Shanghai Allist Pharmaceuticals Co., Ltd., dated June 29, 2021, as amended by Amendment No. 1, dated November 6, 2023

Exhibit 10.12 GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Table of Contents Page 1. DEFINI

Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the closing of this offering)

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ArriVent BioPharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with

Offer Letter Agreement, by and between the Registrant and Winston Kung, MBA, dated January 3, 2024

Exhibit 10.11 January 3, 2024 Winston Kung Dear Winston, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). You will initially serve in the position of Chief Financial Officer & Treasurer, reporting to Bing Yao, CEO; with review for title expansion by or before June 2024. You are tentatively scheduled for a start date of January 4, 2024; with exac

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant None.

2021 Employee, Director and Consultant Equity Incentive Plan, as amended and form of stock option agreement thereunder

Exhibit 10.2 ARRIVENT BIOPHARMA, INC. 2021 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this ArriVent Biopharma, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has deleg

Clinical Collaboration Agreement, by and between the Registrant and Beijing InnoCare Pharma Tech Co., Ltd., dated June 23, 2023

Exhibit 10.15 CLINICAL COLLABORATION AGREEMENT This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Ro

Amended and Restated Investors’ Rights Agreement, dated as of December 16, 2022

Exhibit 4.2 Execution Version AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREA

As filed with the Securities and Exchange Commission on January 5, 2024.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 5, 2024.

Offer Letter Agreement, by and between the Registrant and Robin LaChapelle, dated May 21, 2021

Exhibit 10.9 May 21, 2021 Robin LaChapelle Dear Robin, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are

Second Amended and Restated Certificate of Incorporation, as amended, as currently in effect

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ArriVent BioPharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 ArriVent BioPharma, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to Be Paid Equity Common Stock, par value $0.0001 per share 457(o) —

Offer Letter Agreement, by and between the Registrant and James Kastenmayer, J.D., Ph.D., dated August 11, 2023

Exhibit 10.10 August 11, 2023 Jim Kastenmayer Dear Jim, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). You will serve in the position of General Counsel, reporting to Zhengbin Yao, CEO. You are tentatively scheduled for a start date of Tuesday September 5, 2023; with exact date to be determined. You will receive a base salary of $16,666.67 on

Research Collaboration Agreement, dated December 21, 2021, by and between Aarvik Therapeutics, Inc. and the Registrant, as amended by Amendment No. 1, effective June 30, 2023

  Exhibit 10.14   RESEARCH COLLABORATION AGREEMENT   This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with

Form of Amended and Restated Bylaws (to be effective immediately prior to the closing of this offering)

Exhibit 3.4 ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS (Effective as of [●]) ARTICLE I - STOCKHOLDERS Section 1.       Annual Meeting. An annual meeting of the stockholders of ArriVent BioPharma, Inc. (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held

Specimen Common Stock Certificate

Exhibit 4.1 Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF ArriVent Biopharma, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate

As confidentially submitted to the Securities and Exchange Commission on December 5, 2023. This Amendment No. 3 to the Draft Registration Statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herei

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on December 5, 2023.

JOINT CLINICAL COLLABORATION AGREEMENT

Exhibit 10.12 JOINT CLINICAL COLLABORATION AGREEMENT This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New D

GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT ArriVent Biopharma, Inc. Shanghai Allist Pharmaceuticals Co., Ltd.

Exhibit 10.11 GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Table of Contents Page 1. DEFINI

CLINICAL COLLABORATION AGREEMENT

Exhibit 10.14 CLINICAL COLLABORATION AGREEMENT This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Ro

  RESEARCH COLLABORATION AGREEMENT

  Exhibit 10.13   RESEARCH COLLABORATION AGREEMENT   This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with

Boston Los Angeles New York San Diego San Francisco TORONTO Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com December 5, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Suzanne Hayes, Office of Life Sciences Re: ArriVent BioPharma, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted October 31, 2023 CIK No. 0001868279

As confidentially submitted to the Securities and Exchange Commission on October 31, 2023. This Amendment No. 2 to the Draft Registration Statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herei

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on October 31, 2023.

August 11, 2023

Exhibit 10.10 August 11, 2023 Jim Kastenmayer 19937 Bodmer Avenue Poolesville, MD 20837 Dear Jim, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). You will serve in the position of General Counsel, reporting to Zhengbin Yao, CEO. You are tentatively scheduled for a start date of Tuesday September 5, 2023; with exact date to be determined. You wi

Boston        Los Angeles        New York        San Diego         San Francisco        TORONTO         Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com October 31, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Suzanne Hayes, Office of Life Sciences Re: ArriVent BioPharma, Inc. Amended Draft Registration Statement on Form S-1 Submitted October 4, 2023 CIK No. 0001868279 (the “Amende

ARRIVENT BIOPHARMA, INC. CLAWBACK POLICY

Exhibit 10.6 ARRIVENT BIOPHARMA, INC. CLAWBACK POLICY I.             Introduction The Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Th

CLINICAL COLLABORATION AGREEMENT

Exhibit 10.14 CLINICAL COLLABORATION AGREEMENT This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Ro

ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS (Effective as of [●]) ARTICLE I - STOCKHOLDERS

Exhibit 3.4 ARRIVENT BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS (Effective as of [●]) ARTICLE I - STOCKHOLDERS Section 1.       Annual Meeting. An annual meeting of the stockholders of ArriVent BioPharma, Inc. (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held

ARRIVENT BIOPHARMA, Inc. EXECUTIVE SEVERANCE PLAN

Exhibit 10.4 ARRIVENT BIOPHARMA, Inc. EXECUTIVE SEVERANCE PLAN 1.            Establishment; Purpose. ArriVent, Inc. (the “Company”) hereby establishes as of [●], 2023 an unfunded severance benefit plan (this “Plan”) for its Eligible Employees in order to establish the conditions under which the Eligible Employees will receive the severance payments and benefits described herein if their employment

ARRIVENT BIOPHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (_____, 2023)

Exhibit 10.5 ARRIVENT BIOPHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (, 2023) The Board of Directors of ArriVent BioPharma, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective upon the completion of the Company’s initial public offering (“E

  RESEARCH COLLABORATION AGREEMENT

  Exhibit 10.13   RESEARCH COLLABORATION AGREEMENT   This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware)

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ArriVent BioPharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with

Indemnification Agreement

Exhibit 10.1 Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made and entered into this []th day of [], 2023, by and between ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). Recitals Whereas, qualified persons are reluctant to serve corporations as directors or otherwise unless they are provided with broad indemnification and i

JOINT CLINICAL COLLABORATION AGREEMENT

Exhibit 10.10 JOINT CLINICAL COLLABORATION AGREEMENT This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New D

  RESEARCH COLLABORATION AGREEMENT

  Exhibit 10.11   RESEARCH COLLABORATION AGREEMENT   This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with

GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT ArriVent Biopharma, Inc. Shanghai Allist Pharmaceuticals Co., Ltd.

Exhibit 10.9 GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd. [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Table of Contents Page 1. DEFINIT

As confidentially submitted to the Securities and Exchange Commission on October 4, 2023. This Amendment No. 1 to the Draft Registration Statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on October 4, 2023.

Boston Los Angeles New York San Diego San Francisco TORONTO Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center Boston, MA 02111 617 542 6000 mintz.com October 4, 2023 VIA EDGAR & OVERNIGHT MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Suzanne Hayes, Office of Life Sciences Re: ArriVent BioPharma, Inc. Draft Registration Statement on Form S-1 Submitted August 25, 2023 CIK No. 0001868279 (the

May 21, 2021

Exhibit 10.8 May 21, 2021 Robin LaChapelle Dear Robin, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are

ARRIVENT BIOPHARMA, INC. 2021 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN

Exhibit 10.2 ARRIVENT BIOPHARMA, INC. 2021 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this ArriVent Biopharma, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has deleg

SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware)

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARRIVENT BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ArriVent BioPharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1

As confidentially submitted to the Securities and Exchange Commission on August 25, 2023. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confi

TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on August 25, 2023.

ARRIVENT BIOPHARMA, INC. SECOND AMENDED AND RESTATED BYLAWS Adopted as of December 16, 2022

Exhibit 3.3 ARRIVENT BIOPHARMA, INC. SECOND AMENDED AND RESTATED BYLAWS Adopted as of December 16, 2022 1 Table of Contents Page(s) ARTICLE I STOCKHOLDERS 1 Section 1. Annual Meeting 1 Section 2. Special Meetings 1 Section 3. Notice of Meetings 1 Section 4. Quorum 2 Section 5. Organization 2 Section 6. Conduct of Business 2 Section 7. Proxies and Voting 2 Section 8. Action without Meeting 3 Sectio

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

Exhibit 4.4 Execution Version AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREA

May 1, 2021

Exhibit 10.7 May 1, 2021 Stuart Lutzker Dear Stuart, I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are m

May 5, 2021

Exhibit 10.6 May 5, 2021 Bing Yao Dear Bing I am pleased to confirm our offer of employment to you with ArriVent Biopharma, Inc. (“the Company”). This offer of employment is conditioned on, and will not become effective unless and until, the Company closes a financing round with third party investors of at least $90 million (the “Employment Conditions”). If the Employment Conditions are met and yo

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant None.